Commentary: Prevention of saphenous vein graft disease remains elusive

Area of Science:

• Cardiology
• Vascular Surgery
• Clinical Trials

Background:

• Coronary artery bypass grafting (CABG) is a common procedure to treat coronary artery disease.
• Antiplatelet therapy is crucial post-CABG to prevent graft occlusion and cardiovascular events.
• Ticagrelor is a P2Y12 inhibitor with potential benefits in preventing thrombotic events.

Purpose of the Study:

• To compare the efficacy of ticagrelor versus aspirin in maintaining saphenous vein graft patency at one year post-CABG.
• To evaluate the impact of ticagrelor on major adverse cardiovascular events (MACE) in patients following CABG.

Main Methods:

• The study was a randomized, double-blinded clinical trial named TARGET (Ticagrelor Antiplatelet Therapy to Reduce Graft Events and Thrombosis).
• Participants received either ticagrelor or aspirin as post-coronary artery bypass surgery antiplatelet therapy.
• One-year outcomes, including saphenous vein graft patency and MACE, were assessed.

Main Results:

• No statistically significant difference was found in saphenous vein graft patency at one year between the ticagrelor and aspirin groups.
• Similarly, no significant difference in major adverse cardiovascular events was observed between the two treatment arms.
• The study highlighted limitations in design and execution that necessitate cautious interpretation of findings.

Conclusions:

• Ticagrelor did not demonstrate a statistically significant advantage over aspirin for one-year saphenous vein graft patency or MACE after CABG.
• The findings suggest that current antiplatelet strategies may need further optimization.
• Important limitations in the trial warrant caution in interpreting the results and suggest the need for further investigation.